Hennion & Walsh Asset Management, Inc. Vir Biotechnology, Inc. Transaction History

Hennion & Walsh Asset Management, Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 22, 2024	SELL	$7.26 - $10.7 $26,789 - $39,483	-3,690 Reduced 9.5%	35,132 $263,000
Q2 2024 Jul 19, 2024	SELL	$7.63 - $12.66 $2,502 - $4,152	-328 Reduced 0.84%	38,822 $345,000
Q1 2024 Apr 17, 2024	BUY	$8.6 - $11.9 $42,286 - $58,512	4,917 Added 14.36%	39,150 $396,000
Q4 2023 Jan 10, 2024	SELL	$7.76 - $10.29 $3,717 - $4,928	-479 Reduced 1.38%	34,233 $344,000
Q3 2023 Oct 27, 2023	BUY	$9.14 - $24.62 $22,886 - $61,648	2,504 Added 7.77%	34,712 $325,000
Q2 2023 Aug 09, 2023	BUY	$23.2 - $27.29 $14,732 - $17,329	635 Added 2.01%	32,208 $790,000
Q1 2023 Apr 20, 2023	BUY	$22.26 - $30.85 $119,269 - $165,294	5,358 Added 20.44%	31,573 $735,000
Q4 2022 Jan 12, 2023	BUY	$19.96 - $28.22 $523,251 - $739,787	26,215 New	26,215 $664,000

231

90.1M

1.28M

235K

Ticker VIR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 132,638,000
Market Cap $1.27B
Description
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 fo...

Get notified when there are updates to the investment portfolio of Hennion & Walsh Asset Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Hennion & Walsh Asset Management, Inc. with notifications on news.